Accredited Investor? We Have a Deal Available Right Now! Click Here to Schedule a Call and Get Full Access

FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 09/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 09/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of September 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 6,494m
  • Biotech received 45% of the total investment volume (-1% compared to the previous month)
  • Oncology dominates as the top indication in Biotech
  • CMR Surgical (United Kingdom) has the highest transaction volume of EUR 142m in September, followed by Rejuveron (Switzerland) EUR 69m and Corteria Pharmaceuticals (France) EUR 65m
  • The European Innovation Council Fund (Belgium) dominates the Top 5 Investors (by deal volume), followed by Revival Healthcare Capital (United States) and Gilde Healthcare Partners (Netherlands)
  • Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.

By Mathias Klozenbücher,  Johannes Link and Marco Buonafede-Bennardo.

Source link

Related Articles